Biotech Values

[DewDiligence]

USPTO rejects Teva’s attempt to re-issue ‘808 Copaxone patent:

http://finance.yahoo.com/news/united-states-pto-rejects-tevas-182700922.html

This is paradoxically a good outcome for Teva now that the USSC has decided to review the ‘808 patent case on procedural grounds. If the PTO had re-issued the ‘808 patent (with Teva’s changes) under a new patent number, Teva would have had to disclaim the original ‘808 patent, which would have made the USSC review null and void.

Note: The PR referenced above is from MYL.